Oncology Pharma Meeting Towards Future Developments
December 17 2021 - 8:11AM
InvestorsHub NewsWire
San Francisco, CA -- December 17, 2021 -- InvestorsHub
NewsWire -- Oncology Pharma
Inc. (OTC: ONPH) Oncology Pharma, Inc. ("The
Company") conducted a meeting with the Board of Directors,
executives, and Scientific Advisory Board members along with legal
counsel, which shared updates on progress made towards the
development of the Company's licensed products. This marked
progress towards pursuing its primary goal of the Co-Development
plan to bring new pharmaceutical drug formulations to market with a
focused approach that aims to reduce overall costs and minimize
time and duration to commercialization.
During the meeting, the Boards were advised and discussed
advantages of pursuing specific technologies, such as the
Connect2Med trials program with Ribeira Solutions along with
pediatric and orphan drug designations and possible strategies to
pursue for a Company of its size. Amongst that focus is
the nanoemulsion of dactinomycin. The Company and its
partners are currently undertaking the creation and testing of
targeted formulations to include in the studies that will be
submitted to in depth trials.
Oncology Pharma has developed the framework and is conducting
early feasibility and initial non-clinical studies; and is in the
process of creating data that focuses on using its dactinomycin
nanoemulsion drug product, intended for the treatment of pediatric
cancers. Dactinomycin has been shown to be effective in
destroying cancer cells. Utilizing the Nanoemulsion for the
targeted delivery system is expected to allow a safe dose of the
drug to be delivered over time, so it may be safely
administered. The Company anticipates as data is created that
there will be more developments and opportunities to pursue.
With early indications confirming initial assumptions, the work so
far has been encouraging and proceeding on schedule.
ABOUT ONCOLOGY PHARMA,
INC.
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently
engaging in research and development of therapeutics for oncology
and prides itself for having a world-class Advisory Board that
keeps the Company in the forefront of developing technologies in
cancer research, biotechnology, and healthcare.
FORWARD LOOKING
STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Aug 2023 to Aug 2024